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ABSTRACT
A small library of cholesterol-piperazine conjugates were synthesized by the reaction of cholesteryl chloroformate with a set of
substituted piperazines in dichloromethane at room temperature. The conjugates, all obtained in good to excellent yields, were
synthesized to be key components of nucleic acid transfection lipoplexes.
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1. Introduction
In recent years lipoplexes have been utilized as nucleic acid
transfer agents in attempts to transfect cells with DNA and RNA,
with varying degrees of success. This area has been the focus of
much research activity and a number of reviews have summa-
rized the highlights in the area.1 In terms of the lipoplex
nanostructures utilized to perform the cellular transfection, one
of their major components usually consists of a lipophillic ‘tail’
portion (fatty acid, steroid etc.) with a positively charged polar
‘head’ group to facilitate charged complexation with the nega-
tively charged nucleic acid sequence to be transported. One of
the most popular lipophillic groups utilized in this field has been
cholesterol and representative examples are shown in Fig. 1
(compounds 1–4).
The examples shown in Fig. 1 include cholesterol conjugated
to a linear polyamine, such as spermine, using a carbamate
linker, arranged in a linear (compound 12) or a ‘T-shaped’
(compound 23) manner. Other researchers have opted for the
use of cyclic amines to provide the cationic head group under
physiological conditions. For instance, Gao and Hui utilized a
piperazine head group as shown in compounds 3 and 4.4
Intrigued by these latter results, our research group decided to
do a systematic study into the ability of cholesterol-piperazine
conjugates to perform as components of gene delivery vehicles.5
The synthetic aspects of this work are described in this paper.6
2. Results and Discussion
As illustrated in Fig. 1, the use of a piperazine head group to
form cholesterol-piperazine conjugates has been investigated.4
However, the strategy used by these researchers was not
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Figure 1a Examples of previously synthesized polyamine-and piperazine-cholesterol conjugates.
systematic, nor was a diverse set of differentially substituted
piperazines utilized. It was thus decided to synthesize a diversi-
fied library of substituted piperazines, covalently attached via a
carbamate unit to cholesterol. The synthetic strategy involved
reaction of the commercially-available cholesteryl chloroformate
with the desired substituted piperazines in dichloromethane at
room temperature (Scheme 1). After the reactions were complete
(monitored by tlc), the desired compounds were purified by
silica gel column chromatography. All the compounds were
characterized by 1H, 13C NMR and IR spectroscopy and the
molecular masses confirmed by mass spectroscopy.
The first set of compounds that were synthesized contained
simple piperazines. These piperazines were unsubstituted or
bore only simple alkyl, allyl, amine, cyano and ester substituents
(for piperazine structures and reaction yields see Table 1). The
ease with which the compounds were synthesized is demon-
strated by the fact that all the products were obtained in good
yields (>75 %). Compounds synthesized included those with a
piperazine (6a), dimethyl- (6b), N-methyl- (6c) or N-ethyl-
piperazine (6d) moiety. In addition, piperazines bearing short
alkyl amine pendant chains were also synthesized, namely the
N,N-dimethylpropyl and N,N-dimethylethyl derivatives (6e)
and (6f), respectively (Table 1). Both these compounds have the
advantage in that they bear an additional amine group which
can be protonated under physiological conditions. This should
increase the cationic charge required for the lipoplexes to
transfect the negatively charged RNA or DNA sequences. Other
piperazine derivatives were also obtained which included
piperazines bearing groups such as N-allyl (6i) and (6j), ester (6h)
and cyano (6g) functional groups. Compounds (6i) and (6j) are
of interest because they are amenable to further synthetic trans-
formations using, in particular, an envisaged cross metathesis
reaction7 (Table 1). Finally, the N-amino-piperazine-cholesterol
conjugate (7) was also synthesized by the reaction of (5) with
4-methylpiperazin-1-amine (8),4 utilizing the simple synthetic
methodology shown in Scheme 2.
NMR spectral analysis confirmed that the compounds (6a–j)
and 7 had been efficiently synthesized. Apart from the character-
istic signals for cholesterol in the 1H and 13C NMR spectra, signals
for the methylene protons of the piperazine ring at about δ 2.5
and δ 3.5 were evident for most new compounds. In addition,
the 13C NMR spectra displayed a characteristic signal at about
δ 155 for the newly formed carbamate carbonyl.
Interestingly, during the synthesis of the cholest-5-en-3-yl
1-piperazinecarboxylate (6a) a reasonable amount (16 %) of the
symmetrical bis-cholesterol (9) was obtained (Scheme 3). The fact
that double addition of the cholesteryl moiety had occurred
was confirmed by the NMR spectrum, as well as the high-resolu-
tion mass spectrum. A double addition also occurred when
2-(piperazin-1-yl)ethanamine (10) was utilized to obtain com-
pound (11) as shown in Scheme 3. This compound was isolated
in a yield of 78 % based on cholesteryl chloroformate, indicating
that the primary amine was successfully competing with the
secondary amine for the cholesteryl chloroformate substrate. It
is important to note that bis-cholesterol-substituted lipoplex
components have previously been utilized for gene transfection
with varying results.4,8 The isolated products (9) and (11) require
further evaluation for their ability to function as transfection
agents in lipoplexes and this will be performed in future
bioactivity studies.
Finally, a set of cholesteryl derivatives, containing piperazines
substituted with additional aromatic groups, were synthesized
(Table 2). These included the pyridine substituted piperazines
(6k) and (6l), as well as the 2-pyrimidine (6m). Of note is that
other pyridinium-based cationic lipid conjugates have been
successfully used as gene transfer agents.9 Finally, a number of
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Scheme 1
General reaction scheme for synthesis of piperazine-cholesterol conjugates. For yields see Tables 1 and 2.
Figure 1b Examples of previously synthesized polyamine-and piperazine-cholesterol conjugates.
simple aromatic-piperazine cholesterol derivatives were obtained
to complete the small library; these included the phenyl (6n),
2-fluorophenyl (6o), 4-fluorophenyl (6p) and the oxygenated
phenyl (6q)-substituted piperazine head groups and once again
the products were all obtained in excellent yields (Table 2).
3. Conclusion
In this paper we have disclosed the synthesis of a diverse
library of cholesterol derivatives conjugated to substituted
piperazines by way of a carbamate linker. An advantage of the
strategy utilized was that it afforded the desired compounds in
high yields. Moreover, the approach allowed for incorporation
of functional diversity on the piperazine head group because of
the significant variety of commercially available substituted
piperazines. Initial studies5 have shown that a number of the
synthesized piperazine-cholesterol conjugates have potential as
gene transfer agents but further investigations need to be
performed, including the use of in vivo mouse models.
4. Experimental
1H NMR and 13C NMR spectra were recorded on a Bruker
AVANCE 300 spectrometer at the frequency indicated. J-Values
are given in Hz. Infrared spectra were recorded on a Bruker
Vector 22 Fourier Transform spectrometer. High resolution
electrospray ionization mass spectra (ESI-FTMS) were recorded
at the Technical University Dortmund, Germany, using a
Thermo LTQ Orbitrap (high resolution mass spectrometer from
Thermo Electron) coupled to an ‘Accela’ HPLC System supplied
with a ‘Hypersil GOLD’ column (Thermo Electron). Macherey-
Nagel Kieselgel 60 (particle size 0.063–0.200 mm) was used for
conventional silica gel chromatography. All solvents used for
reactions and chromatography were distilled prior to use to
remove residual non-volatiles. Removal or concentration of
solvent in vacuo implies the evaporation of solvent at 20–25 Torr
utilizing a rotary evaporator. Melting points are reported as
uncorrected.
General procedure for the synthesis of compounds 6a–q: The
substituted piperazines (1 mmol) and NEt3 (1.5 mmol) were
dissolved in CH2Cl2 (10 mL). The solution was cooled to 0oC and
cholesteryl chloroformate (1 mmol) in CH2Cl2 (10 mL) was then
added over 10 min. Then the solution was stirred for 10 min. The
reaction mixture was then stirred 4–8 h at rt under N2. The
reaction mixture was then washed with water (3 × 10 mL) and
the organic phase dried (MgSO4) before being removed under
reduced pressure to give a crude solid. This solid was then
purified by silica gel chromatography (2–10 % MeOH/CH2Cl2) to
afford the desired compounds in good to excellent yields.
Cholest-5-en-3-yl 1-piperazinecarboxylate 6a. Yield: 84 %; mp:
140–142 °C IR: 2945, 2863, 1687, 1427 cm–1; 1H NMR (300 MHz,
CDCl3): 0.68 (s, 3H, CH3), 0.86 (d, 6H, J = 6.0, 2 × CH3), 0.92 (d, 3H,
J = 6.0, CH3), 1.02 (s, 3H, CH3), 0.85–1.59 (m, 23H), 1.83–2.03 (m,
5H), 2.28–2.35 (m, 2H), 2.80–2.84 (m, 4H, NCH2), 3.41–3.45 (m, 4H,
NCH2), 4.46–4.57 (m, 1H), 5.37 (brs, 1H); 13C NMR (75 MHz,
CDCl3): 11.8, 18.6, 19.3, 21.0, 22.5, 22.7, 23.8, 24.2, 27.9, 28.2, 31.8,
31.8, 35.7, 36.1, 36.5, 36.9, 38.6, 39.4, 39.7, 42.2, 44.7, 45.8, 49.9, 56.1,
56.6, 74.7, 122.3, 139.8, 155.0; MS 499 (M+,100 %), 369 (20), HRMS:
(M + H)+ C32H56O2N2 Calculated 499.4258, Found 499.4250.
Cholest-5-en-3-yl 3,5-dimethyl-1-piperazinecarboxylate 6b.
Yield: 89 %; mp: 174–176 °C IR: 2932, 2898, 1691, 1682, 1531 cm–1;
1H NMR (300 MHz, CDCl3): 0.68 (s, 3H, CH3), 0.87 (d, 6H, J = 6.0,
2 × CH3), 0.92 (d, 3H, J = 6.0, CH3), 1.02 (s, 3H, CH3), 1.34 (d, 6H,
J = 6.0, 2 × CH3), 0.85–1.64 (m, 22H), 1.77–2.04 (m, 5H), 2.25–2.40
(m, 2H), 2.70–2.86 (m, 2H), 2.95–3.09 (m, 2H), 4.08–4.16 (m, 2H),
4.47–4.58 (m, 2H), 5.37–5.38 (d, 1H, J = 4); 13C NMR (75 MHz,
CDCl3): 11.8, 17.2, 18.6, 19.3, 21.0, 22.5, 22.7, 23.8, 24.2, 27.9, 28.1,
31.8, 31.9, 35.7, 36.1, 36.5, 36.9, 38.5, 39.4, 39.7, 42.2, 48.0 br, 49.9,
51.7, 56.1, 56.6, 75.4, 122.6, 139.6, 154.4; MS: 600 (15 %), 527 (100);
HRMS: (M + H)+ C34H59N2O2 Calculated 527.4571, Found
527.4563.
Cholest-5-en-3-yl 4-methyl-1-piperazinecarboxylate 6c. Yield:
79 %; mp: 135–137 °C; IR: 2932, 2864, 1697, 1430 cm–1 ; 1H NMR
(300 MHz, CDCl3): 0.68 (s, 3H, CH3), 0.86 (d, 6H, J = 6.0, 2 × CH3),
0.91 (d, 3H, J = 6.0, CH3), 1.02 (s, 3H, CH3), 0.85–1.58 (m, 23H),
1.83–2.03 (m, 5H), 2.29 (s, 4H, NCH2), 2.35 (s, 4H, 2 × NCH2), 3.48
(s, 3H, NCH3), 4.48–4.55 (m, 1H), 5.37 (s, 1H); 13C NMR (75 MHz,
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Table 1 Cholesterol conjugated to piperazines substituted with alkyl
side chains (refer to Scheme 1 for reaction scheme).
Entry (6) Piperazine Yield
1 a 84 %
2 b 89 %
3 c/(4)4 79 %
4 d 81 %
5 e 89 %
6 f 83 %
7 g 78 %
8 h 80 %
9 i 83 %
10 j 87 %
CDCl3): 11.8, 18.7, 19.3, 21.0, 22.5, 22.7, 23.8, 24.2, 28.0, 28.2, 31.8,
35.7, 36.1, 36.5, 37.0, 38.6, 39.5, 39.7, 42.3, 43.5 br, 46.0, 50.0, 54.7,
56.1, 56.6, 74.8, 122.4, 139.8, 155.0; MS 586 (30 %), 513 (M+, 100);
HRMS: (M + H)+ C33H57O2N2. Calculated 513.4415, Found
513.4407.
Cholest-5-en-3-yl 4-ethyl-1-piperazinecarboxylate 6d. Yield:
81 %; mp: 164–166 °C IR: 2933, 2898, 1694, 1684, 1455 cm–1;
1H NMR (300 MHz, CDCl3): 0.68 (s, 3H, CH3), 0.87 (d, 6H, J = 6.0,
2 × CH3), 0.92 (d, 3H, J = 6.0, CH3), 1.02 (s, 3H, CH3), 1.08–1.68 (m,
25H), 1.83–2.03 (m, 5H), 2.24–2.46 (m, 8H), 3.47–3.51 (m, 4H, 2 ×
NCH2), 4.46–4.55 (m, 1H), 5.36–5.37 (brs, 1H); 13C NMR (75 MHz,
CDCl3): 11.8, 11.8, 18.7, 19.4, 21.0, 22.5, 22.7, 22.9, 23.8, 24.2, 27.9,
28.2, 31.8, 31.8, 35.7, 36.1, 36.5, 37.0, 38.6, 39.5, 39.7, 42.3, 50.0, 52.5,
56.1, 56.6, 74.8, 76.5, 122.4, 139.8, 154.9; MS: 527 (100 %), HRMS:
(M + H)+ C34H59N2O2 Calculated 527.4571, Found 527.4562.
Cholest-5-en-3-yl 4-[2-(dimethylamino)ethyl]-1-piperazine-
carboxylate 6e. Yield: 89 %; mp: 194–196 °C IR: 2943, 2890, 1738,
1727, 1458, 1423 cm–1; 1H NMR (300 MHz): 0.68 (s, 3H, CH3), 0.86
(d, 6H, J = 6.0, 2 × CH3), 0.91 (d, 3H, J = 6.0, CH3), 1.02 (s, 3H,
CH3), 0.85–1.68 (m, 21H), 1.82–2.04 (m, 5H), 2.24–2.35 (m, 2H),
2.27–2.49 (m, 4H), 2.79 (s, 6H, 2 × N(CH3)2), 2.79–2.83 (m, 2H),
2.97–3.01 (m, 2H), 3.49–3.52 (m, 4H), 4.46–4.54 (m, 1H), 5.37 (brs,
1H); 13C NMR (75 MHz): 11.7, 18.6, 19.2, 20.9, 22.4, 22.7, 23.7, 24.2,
27.9, 28.1, 31.8, 31.8, 35.7, 36.1, 36.5, 36.9, 38.5, 39.4, 39.6, 42.2, 44.1,
49.9 (× 2), 52.8, 56.0, 56.6, 74.9, 122.3, 139.7, 154.8 (some C over-
lapping/not observed); MS: 618 (15 %), 570 (100), HRMS: (M +
H)+ C36H64N3O2 Calculated 570.4993, Found 570.4986.
Cholest-5-en-3-yl 4-[3-(dimethylamino)propyl]-1-piperazine-
carboxylate 6f. Yield: 83 %; mp: 113–115 °C; IR: 2943, 2888, 1738,
1699, 1457, 1431 cm–1; 1H NMR (300 MHz, CDCl3): 0.68 (s, 3H,
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Scheme 2
Synthesis of N-amino-piperazine-cholesterol conjugate (7).
Scheme 3
Synthesis of bis-cholesterol piperazine conjugates.
CH3), 0.86 (d, 6H, J = 6.0, 2 × CH3), 0.92 (d, 3H, J = 6.0, CH3), 1.02
(s, 3H, CH3), 0.95–1.71 (m, 23H), 1.83–2.03 (m, 5H), 2.22 (brs, 6H),
2.29 (t, 2H, J = 5.5), 2.35–2.41 (m, 8H), 3.46–3.49 (m, 4H), 4.46–4.56
(m, 1H), 5.37 (brs, 1H); 13C NMR (75 MHz, CDCl3): 11.8, 18.6, 19.3,
21.0, 22.5, 22.7, 23.8, 24.2, 25.0, 27.9, 28.2, 31.8, 31.8, 35.7, 36.1, 36.5,
37.0, 38.6, 39.5, 39.7, 42.2, 43.6 br, 45.4 (× 2), 49.9, 52.9, 56.1, 56.6,
57.8, 74.7, 122.3, 139.8, 154.9; MS: 584 (85 %), 369 (100), 216 (70),
HRMS: (M + H)+ C37H66N3O2 Calculated 584.5150, Found
584.5146.
Cholest-5-en-3-yl 4-(2-cyanoethyl)-1-piperazinecarboxylate
6g. Yield: 78 %; mp: 172–174 °C; IR: 3316, 2931, 2897, 1692, 1682,
1454 cm–1; 1H NMR (300 MHz, CDCl3): 0.67 (s, 3H, CH3), 0.86 (d,
6H, J = 6.0, 2 × CH3), 0.92 (d, 3H, J = 6.0, CH3), 1.02 (s, 3H, CH3),
0.95–1.62 (m, 22H), 1.79–2.03 (m, 5H), 2.24–2.52 (m, 8H), 2.70 (t,
2H, J = 6.6), 3.47–3.50 (m, 4H), 4.45–4.58 (m, 1H), 5.36 (brs, 1H);
13C NMR (75 MHz, CDCl3): 11.8, 15.9, 18.7, 19.3, 20.9, 22.5, 22.8,
23.7, 24.2, 27.9, 28.1, 31.8, 35.7, 36.1, 36.5, 36.9, 38.5, 39.4, 39.7, 42.3,
43.4 br, 49.9, 52.3, 53.3, 56.0, 56.6, 75.0, 118.5, 122.5, 139.8, 154.9
(CN); MS: 625 (50 %), 552 (100), 369 (40), HRMS: (M + H)+
C35H58N3O2 Calculated 552.4524, Found 552.4516.
1-Cholest-5-en-3-yl 4-ethyl 1,4-piperazinedicarboxylate 6h.
Yield: 80 %; mp: 126–128 °C; IR: 2932, 2861, 1682, 1454 cm–1;
1H NMR (300 MHz, CDCl3): 0.68 (s, 3H, CH3), 0.86 (d, 6H, J = 6.0,
2 × CH3), 0.91 (d, 3H, J = 6.0, CH3), 1.02 (s, 3H, CH3), 1.27 (t, 3H,
J = 7.1, OCH2CH3), 0.95–1.66 (m, 21H), 1.77–2.03 (m, 5H),
2.25–2.41 (m, 2H), 3.45 (brs, 8H), 4.15 (q, 2H, J = 7.1, OCH2CH3),
4.48–4.58 (m, 1H), 5.36–5.38 (m, 1H); 13C NMR (75 MHz, CDCl3):
11.8, 14.5, 18.5, 19.2, 20.8, 22.4, 22.6, 23.7, 24.2, 27.8, 28.0, 28.2, 31.8,
35.6, 36.1, 36.4, 36.9, 38.4, 39.4, 39.6, 42.1, 43.3 br, 49.8, 55.9, 56.5,
61.5, 76.4, 122.5, 139.6, 154.9, 155.3; MS: 1141 (30%), 414 (20), 372
(100), 299 (60), 166 (40); HRMS: (2M+H)+ C70H117O8N4 Calculated
1141.8866, Found 1141.8877.
Cholest-5-en-3-yl 4-allyl-1-piperazinecarboxylate 6i. Yield:
83 %; mp: 210–212 °C; IR: 2940, 1697, 1419 cm–1; 1H NMR
(300 MHz, CDCl3): 0.68 (s, 3H, CH3), 0.86 (d, 6H, J = 6.0, 2 × CH3),
0.92 (d, 3H, J = 6.0, CH3), 1.02 (s, 3H, CH3), 1.06–1.59 (m, 22H),
1.83–2.03 (m, 5H), 2.25–2.40 (m, 2H), 2.97 (brs, 4H), 3.52 (d, 2H, J =
6.9), 3.88 (brs, 4H), 4.47–4.57 (m, 1H), 5.33–5.37 (m, 3H), 6.07–6.20
(m, 1H); 13C NMR (75 MHz, CDCl3): 11.8, 18.6, 19.2, 20.9, 22.4,
22.7, 23.7, 24.2, 27.9, 28.0, 28.1, 31.8, 31.8, 35.7, 36.1, 36.4, 36.8, 38.4,
39.4, 39.6, 41.0 br, 42.2, 49.9, 51.3, 56.0, 56.6, 60.1, 75.7, 122.7, 124.9
br, 127.4 br, 139.4, 154.3; MS: 539 (100 %), HRMS: (M + H)+
C35H59N2O2 Calculated 539.4571, Found 539.4563.
Cholest-5-en-3-yl 4-allyl-3,5-dimethyl-1-piperazinecarboxy-
late6j. Yield: 87 %; mp: 88–90 °C; IR: 3316, 2932, 2865, 1738, 1692,
1455 cm–1; 1H NMR (300 MHz, CDCl3): 0.68 (s, 3H, CH3), 0.86 (d,
6H, J = 6.0, 2 × CH3), 0.92 (d, 3H, J = 6.0, CH3), 1.02 (s, 3H, CH3),
1.25 (d, 6H, J = 6.0, 2 × CH3), 0.92–1.62 (m, 20H), 1.78–2.11 (m,
5H), 2.22–2.39 (m, 3H), 2.60–2.65 (m, 1H), 2.90–2.97 (m, 2H),
3.04–3.10 (m, 2H), 3.28–3.33 (m, 1H), 3.70 (d, 1H, J = 12.9),
4.24–4.27 (m, 1H), 4.47–4.58 (m, 1H), 5.12 (d, 1H, J = 10.2), 5.18
(dd, 1H, J = 1.2, 18.9), 5.36–5.37 (brs, 1H), 5.74–5.87 (m, 1H);
13C NMR (75 MHz, CDCl3): 7.4, 11.8, 16.2, 18.7, 19.3, 21.0, 22.5,
22.7, 23.9, 24.2, 27.9, 28.2, 28.3, 31.8, 31.9, 35.7, 36.1, 36.5, 36.9, 38.5,
38.6, 39.4, 39.6, 42.2, 44.4, 46.9, 48.8, 49.9, 52.2, 56.0, 56.6, 57.8, 74.5,
116.9, 122.3, 135.9, 139.8, 139.9, 155.5; MS: 567 (100 %), HRMS:
(M + H)+ C37H63N2O2 Calculated 567.4884, Found 567.4876.
Cholest-5-en-3-yl 4-(2-pyridinyl)-1-piperazinecarboxylate 6k.
Yield: 91 %; mp: 95–97 °C; IR: 2943, 1727, 1705, 1459 cm–1; 1H NMR
(300 MHz, CDCl3): 0.68 (s, 3H, CH3), 0.86 (d, 6H, J = 6.0, 2 × CH3),
0.91 (d, 3H, J = 6.0, CH3), 1.00 (s, 3H, CH3), 0.90–1.75 (m, 21H),
1.82–1.99 (m, 5H), 2.32–2.39 (m, 2H), 3.53–3.59 (m, 8H), 4.50–4.61
(m, 1H), 5.38 (brs, 1H), 6.62–6.66 (m, 2H, ArH), 7.46–7.49 (m, 1H,
ArH), 8.18–8.20 (m, 1H, ArH); 13C NMR (75 MHz, CDCl3): 11.8,
18.7, 19.3, 21.0, 22.5, 22.8, 23.8, 24.2, 27.9, 28.2, 31.8, 31.9, 35.7, 36.1,
36.5, 36.9, 38.6, 39.4, 39.7, 42.3, 43.4 br, 45.0, 49.9, 56.1, 56.6, 75.1,
107.2, 113.6, 122.5, 137.5, 139.8, 147.9, 155.0, 159.2; MS: 576
(100 %), HRMS: (M + H)+ C37H58N3O2576.4524, Found 576.4514.
Cholest-5-en-3-yl 4-(4-pyridinyl)-1-piperazinecarboxylate 6l.
Yield: 91 %; mp: 188–190 °C; IR: 2941, 2868, 1738, 1699, 1597,
1542 cm–1; 1H NMR (300 MHz, CDCl3): 0.68 (s, 3H, CH3), 0.86 (d,
6H, J = 6.0, 2 × CH3), 0.91 (d, 3H, J = 6.0, CH3), 1.08 (s, 3H, CH3),
1.07–1.56 (m, 21H), 1.79–1.99 (m, 5H), 2.31–2.38 (m, 2H), 3.31–3.35
(m, 4H), 3.59–3.63 (m, 4H), 4.51–4.61 (m, 1H), 5.38 (brs, 1H), 6.66
(d, 2H, J = 6.6, ArH), 8.29 (d, 2H, J = 6.4, ArH); 13C NMR (75 MHz,
CDCl3): 11.8, 18.6, 19.3, 21.0, 22.5, 22.7, 22.9, 23.8, 24.3, 27.9, 28.2,
31.9, 35.8, 36.2, 36.6, 36.9, 38.6, 39.5, 39.7, 42.3, 42.9, 45.7, 49.9, 56.1,
56.7, 75.2, 108.5 (× 2), 122.6, 139.7, 150.4 (× 2), 154.7, 154.9; MS:
576 (100 %), HRMS: (M + H)+ C37H58N3O2 Calculated 576.4524,
Found 576.4513
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Table 2 Cholesterol conjugated to piperazines substituted with pyri-
dine- and aromatic-bearing side chains (refer to Scheme 1 for reaction
scheme).
Entry (6) Piperazine Yield
12 k 91%
13 l 91 %
14 m 93 %
15 n 89 %
16 o 92 %
17 p 90 %
18 q 92 %
Cholest-5-en-3-yl 4-(2-pyrimidinyl)-1-piperazinecarboxylate
6m. Yield: 93 %; mp: 183–185 °C; IR: 2969, 2865, 1738, 1698, 1544,
1457 cm–1; 1H NMR (300 MHz, CDCl3): 0.68 (s, 3H, CH3), 0.86 (d,
6H, J = 6.0, 2 × CH3), 0.91 (d, 3H, J = 6.0, CH3), 1.03 (s, 3H, CH3),
0.95–1.63 (m, 21H), 1.79–1.94 (m, 5H), 2.28–2.43 (m, 2H), 3.52–3.56
(m, 4H), 3.80–3.84 (m, 4H), 4.51–4.61 (m, 1H), 5.39 (brs, 1H),
6.50–6.53 (m, 1H, ArH), 8.32 (d, 2H, J = 4.8, ArH); 13C NMR
(75 MHz, CDCl3): 11.8, 18.7, 19.3, 21.0, 22.5, 22.8, 23.8, 24.2, 27.9,
28.2, 31.8, 35.7, 36.1, 36.5, 37.0, 38.6, 39.5, 39.7, 42.3, 43.4 (× 2), 49.9,
56.1, 56.6, 75.0,110.2, 122.5, 139.8, 155.1, 157.7 (× 2), 161.6; MS: 577
(100 %), 369 (10), HRMS: (M + H)+ C36H57N4O2 Calculated
577.4476, Found 577.4471.
Cholest-5-en-3-yl 4-phenyl-1-piperazinecarboxylate 6n. Yield:
89 %; mp: 169–171 °C; IR: 2946, 1775, 1683, 1598, 1433 cm–1;
1H NMR (300 MHz, CDCl3): 0.68 (s, 3H, CH3), 0.87 (d, 6H, J = 6.0,
2 × CH3), 0.92 (d, 3H, J = 6.0, CH3), 1.03 (s, 3H, CH3), 0.95–1.65 (m,
21H), 1.81–2.03 (m, 5H), 2.27–2.47 (m, 2H), 3.14 (brs, 4H), 3.63 (brs,
4H), 4.51–4.59 (m, 1H), 5.38 (brs, 1H), 6.87–6.98 (m, 3H, ArH),
7.26–7.31 (m, 2H, ArH); 13C NMR (75 MHz, CDCl3): 11.8, 18.7,
19.3, 21.0, 22.5, 22.8, 23.8, 24.7, 28.0, 28.2, 31.8, 31.9, 35.7, 36.1, 36.5,
36.9, 38.6, 39.4, 39.7, 42.3, 43.6, 49.4, 49.9, 56.0, 56.6, 75.0, 116.6
(× 2), 120.3, 122.5, 129.1 (× 2), 139.7, 151.2, 154.9; MS: 575 (100 %),
HRMS: (M + H)+ C38H59N2O2 Calculated 575.4571, Found
575.4565.
Cholest-5-en-3-yl 4-(2-fluorophenyl)-1-piperazinecarboxylate
6o. Yield: 92 %; mp: 123–125 °C IR: 2938, 1980, 1691, 1543 cm–1;
1H NMR (300 MHz, CDCl3): 0.68 (s, 3H, CH3), 0.87 (d, 6H, J = 6.0,
2 × CH3), 0.92 (d, 3H, J = 6.0, CH3), 1.03 (s, 3H, CH3), 0.95–1.65 (m,
21H), 1.85–2.03 (m, 5H), 2.27–2.47 (m, 2H), 3.04 (brs, 4H), 3.64 (brs,
4H), 4.51–4.59 (m, 1H), 5.39 (brs, 1H), 6.91–7.09 (m, 4H, ArH);
13C NMR (75 MHz, CDCl3): 11.8, 18.6, 19.3, 21.0, 22.5, 22.8, 23.8,
24.2, 27.9, 28.2, 31.8, 35.7, 36.1, 36.5, 36.9, 38.6, 39.4, 39.7, 42.2, 43.7
br, 49.9, 50.4, 56.0, 56.6, 75.0, 116.2 (d, J = 20.8), 119.1 (d, J = 2.7),
122.4, 122.9 (d, J = 3.7), 124.4 (d, J = 7.9), 139.8, 139.9 154.9, 155.8
(d, J = 246.2); MS: 1186 (20 %), 593 (100), 369 (20), HRMS: (M +
H)+ C38H58N2O2F Calculated 593.4477, Found 593.4472.
Cholest-5-en-3-yl 4-(4-fluorophenyl)-1-piperazinecarboxylate
6p. Yield: 90 %; mp: 152–154 °C; IR: 2928, 2864, 1979, 1688, 1512,
1443 cm–1; 1H NMR (300 MHz, CDCl3): 0.67 (s, 3H, CH3), 0.86 (d,
6H, J = 6.0, 2 × CH3), 0.91 (d, 3H, J = 6.0, CH3), 1.02 (s, 3H, CH3),
0.96–1.67 (m, 21H), 1.84–2.02 (m, 5H), 2.27–2.42 (m, 2H), 3.04 (brs,
4H), 3.60–3.63 (m, 4H), 4.50–4.58 (m, 1H), 5.37–5.38 (brs, 1H),
6.85–7.00 (m, 4H, ArH); 13C NMR (75 MHz, CDCl3): 11.8, 18.6,
19.3, 21.0, 22.5, 22.8, 23.8, 24.2, 27.9, 28.2, 31.8, 31.9, 35.7, 36.1, 36.5,
36.9, 38.6, 39.4, 39.6, 42.2, 43.6 br, 50.0, 50.4, 56.0, 56.7, 75.1, 115.6
(d, J = 22.1), 118.5 (d, J = 7.8), 122.5, 139.6, 147.8, 155.0, 157.4 (d,
J = 239.6); MS: 593 (100 %), 369 (15). HRMS: (M + H)+
C38H58N2O2F Calculated 593.4477, Found 593.4471.
Cholest-5-en-3-yl 4-(1,3-benzodioxol-5-ylmethyl)-1-piperazine
carboxylate6q. Yield: 92 %; mp: 115–117 °C; IR: 2940, 2866, 1738,
1698, 1597, 1542 cm–1; 1H NMR (300 MHz, CDCl3): 0.67 (s, 3H,
CH3), 0.86 (d, 6H, J = 6.0, 2 × CH3), 0.91 (d, 3H, J = 6.0, CH3), 1.02
(s, 3H, CH3), 0.90–1.58 (m, 22H), 1.73–2.04 (m, 5H), 2.23–2.37 (m,
6H), 3.41 (s, 2H), 3.45 (s, 4H), 4.45–4.54 (m, 1H), 5.36–5.37 (brs,
1H), 5.94 (s, 2H, OCH2O), 6.70–6.76 (m, 2H, ArH), 6.84 (brs, 1H,
ArH); 13C NMR (75 MHz, CDCl3): 11.8, 18.6, 19.3, 21.0, 22.5, 22.8,
23.7, 24.2, 27.9, 28.1, 31.8, 35.7, 36.1, 36.5, 36.9, 38.6, 39.4, 39.6, 42.2,
43.6 br, 49.9, 52.6, 56.0, 56.6, 62.7, 74.7, 100.8, 107.8, 109.3, 122.1,
122.3, 131.6, 139.8, 146.6, 147.8, 154.9; MS: 633 (100 %), HRMS:
(M + H)+ C40H61N2O4 Calculated 633.46258, Found 633.46170.
Cholest-5-en-3-yl 4-methyl-1-piperazinylcarbamate 7. Yield:
85 %; mp: 166–168 °C; IR: 2937, 2864, 1736, 1717, 1456, 1441 cm–1;
1H NMR (300 MHz, CDCl3): 0.67 (s, 6H, CH3), 0.86 (d, 6H, J = 6.0,
2 × CH3), 0.91 (d, 3H, J = 6.0, CH3), 1.00 (s, 3H, CH3), 0.90–1.68 (m,
21H), 1.75–2.05 (m, 5H), 2.20–2.40 (m, 4H), 2.29 (s, 3H, NCH3),
2.55 (brs, 4H), 2.84 (brs, 4H), 4.49–4.58 (m, 1H), 5.37 (brs, 1H), 5.54
(s, 1H, NH); 13C NMR (75 MHz, CDCl3): 11.8, 18.6, 19.2, 21.0, 22.5,
22.7, 23.7, 24.2, 27.9, 28.1, 31.8, 35.7, 36.1, 36.5, 36.9, 38.5, 39.4, 39.7,
42.2, 45.6, 49.9, 54.3 (× 2), 55.8, 56.1, 56.6, 74.6, 122.5, 139.6, 154.9
br; MS: 528 (100 %), HRMS: (M + H)+ C33H58N3O2 Calculated
528.4524, Found 528.4517.
Dicholest-5-en-3-yl 1,4-piperazinedicarboxylate 9. Yield: 16 %;
mp: 164–166 °C; IR: 2935, 1696, 1567, 1467 cm–1; 1H NMR
(300 MHz, CDCl3): 0.68 (s, 6H, 2 × CH3), 0.86 (2 × d, 12H, J = 6.0,
4 × CH3), 0.92 (d, 6H, J = 6.0, 2 × CH3), 1.02 (s, 6H, 2 × CH3),
0.94–1.64 (m, 42H), 1.77–2.03 (m, 10H), 2.25–2.39 (m, 4H), 3.44
(brs, 8H, NCH2), 4.48–4.58 (m, 2H), 5.38 (brs, 2H); 13C NMR
(75 MHz, CDCl3): 11.8, 18.7, 19.3, 21.0, 22.5, 22.8, 23.8, 24.2, 28.0,
28.2, 31.8, 35.7, 36.1, 36.5, 37.0, 38.6, 39.5, 39.7, 42.3, 43.4 br, 50.0,
56.1, 56.6, 75.2, 122.5, 139.7, 154.9.
Cholest-5-en-3-yl 4-(2-{[(cholest-5-en-3-yloxy)carbonyl]
amino}ethyl)-1-piperazinecarboxylate 11. Yield: 78 % (based
on cholesteryl chloroformate); mp: 140–142 °C; IR: 2943, 2866,
1720, 1703, 1687, 1516, 1464 cm–1 .1H NMR (300 MHz, CDCl3): 0.68
(s, 6H, 2 × CH3), 0.86 (d, 12H, J = 6.0, 4 × CH3), 0.91 (d, 6H, J = 6.0,
2 × CH3), 1.01 (s, 3H, CH3), 1.02 (s, 3H, CH3), 0.95–1.59 (m, 42H),
1.71–2.03 (m, 10H), 2.24–2.49 (m, 10H), 3.27–3.28 (m, 2H),
3.45–3.47 (m, 4H), 4.47–4.55 (m, 2H), 5.07 (brs, 1H, NH), 5.37 (brs,
2H); 13C NMR (75 MHz, CDCl3): 11.8, 18.7, 19.3, 19.3, 21.0, 22.5,
22.8, 23.8, 24.2, 28.0, 28.2, 31.8, 35.7, 36.1, 36.5, 37.0, 37.3 br, 38.5,
38.6, 39.5, 39.7, 42.3, 43.6 br, 50.0, 52.6, 56.1, 56.6, 57.1, 74.3, 74.9,
122.4, 139.8, 139.8, 154.9, 156.0; MS: 954 (100 %), 663 (20), 413 (40),
282 (70); HRMS: (M + H)+ C62H104O4N3 Calculated 954.8021,
Found 954.8026.
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